ISOPRINOSINE Trademark

Trademark Overview

On Tuesday, July 19, 2005, a trademark application was filed for ISOPRINOSINE with the United States Patent and Trademark Office. The USPTO has given the ISOPRINOSINE trademark a serial number of 79017560. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Sunday, June 19, 2022. This trademark is owned by Newport Pharmaceuticals Limited. The ISOPRINOSINE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals, namely, drugs for antiviral and memory enhancement
isoprinosine

General Information

Serial Number79017560
Word MarkISOPRINOSINE
Filing DateTuesday, July 19, 2005
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateSunday, June 19, 2022
Registration Number3171740
Registration DateTuesday, November 14, 2006
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, August 29, 2006

Trademark Statements

Goods and ServicesPharmaceuticals, namely, drugs for antiviral and memory enhancement

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, October 4, 2013
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNewport Pharmaceuticals Limited
Party Type30 - Original Registrant
Legal Entity Type98 - Unknown
AddressIE
Party NameNewport Pharmaceuticals Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressIE
Party NameNewport Pharmaceuticals Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressIE

Trademark Events

Event DateEvent Description
Sunday, January 8, 2023NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Sunday, January 8, 2023DEATH OF INTERNATIONAL REGISTRATION
Sunday, November 21, 2021NEW REPRESENTATIVE AT IB RECEIVED
Friday, April 17, 2015TOTAL INVALIDATION PROCESSED BY THE IB
Sunday, August 3, 2014TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Wednesday, June 4, 2014TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, October 4, 2013CANCELLED SECTION 71
Tuesday, October 23, 2012INTERNATIONAL REGISTRATION RENEWED
Friday, August 31, 2012CHANGE OF NAME/ADDRESS REC'D FROM IB
Friday, March 28, 2008FINAL DECISION TRANSACTION PROCESSED BY IB
Wednesday, June 27, 2007FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, June 27, 2007FINAL DISPOSITION PROCESSED
Wednesday, June 13, 2007FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, December 7, 2006CHANGE OF NAME/ADDRESS REC'D FROM IB
Tuesday, November 14, 2006REGISTERED-PRINCIPAL REGISTER
Tuesday, August 29, 2006PUBLISHED FOR OPPOSITION
Wednesday, August 9, 2006NOTICE OF PUBLICATION
Wednesday, July 5, 2006LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, June 30, 2006ASSIGNED TO LIE
Thursday, June 29, 2006APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, June 29, 2006AMENDMENT FROM APPLICANT ENTERED
Monday, June 5, 2006CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, June 5, 2006PAPER RECEIVED
Tuesday, March 21, 2006CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
Friday, February 24, 2006REFUSAL PROCESSED BY IB
Wednesday, February 8, 2006NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, February 8, 2006REFUSAL PROCESSED BY MPU
Wednesday, February 8, 2006NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, February 7, 2006NON-FINAL ACTION WRITTEN
Tuesday, February 7, 2006ASSIGNED TO EXAMINER
Saturday, December 31, 2005CORRECTION TRANSACTION RECEIVED FROM IB
Friday, December 2, 2005NEW APPLICATION ENTERED IN TRAM
Thursday, December 1, 2005SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB

Related Keywords

isoprinosine memory enhancement antiviral drugs namely pharmaceuticals